Episode Details

GLP-1 drugs like Ozempic, originally for diabetes, are skyrocketing in popularity for weight loss—usage among non-diabetics jumped 600% between 2017 and 2022. While patients pay less out of pocket, overall costs for insurers and government programs have surged 157%, likely driving up premiums and deductibles for everyone. Researchers warn this trend could lead to higher taxes and broader healthcare costs, as the economic ripple effects of this medical breakthrough begin to strain the system. With data from over 20 million adults, experts are calling for smarter, more affordable solutions to balance innovation with accessibility.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/a6fcd66b918df249